Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00223665 · ClinicalTrials.gov registry record · Phase 2
Effects of IAS in Men With Localized Biochemical Relapsed Prostate Cancer
A Phase 2 study, sponsored by University of Washington.
- Completed
- Registry status
- Phase 2
- Development phase
- 102
- Enrollment target
NCT00223665 is a Phase 2 study that has completed, run by University of Washington. The registered enrollment target is 102 participants.
The verdict
NCT00223665, a Phase 2 study, has completed, sponsored by University of Washington.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 102 participants
- Enrollment target
Study Summary
This study was a prospective analysis in men with localized prostate cancer who had rising Prostate Specific Antigen (PSA) levels after definitive treatment with surgery or radiation. Patients received Intermittent Androgen Suppression (IAS) in 9 month cycles until they became metastatic, became castrate resistant, or withdrew from the study. Subjects were monitored for time to development of Castration Resistant Prostate Cancer (CRPC) and overall survival. They were also monitored for the impact of IAS on a variety of neuro-psychiatric assessments and on bone density.
Interventions
- DRUG Leuprolide Acetate
- DRUG Flutamide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 102 participants |
| Start Date | 1997-01-08 |
| Est. Completion | 2012-09-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00223665
The ClinicalTrials.gov registry entry for NCT00223665 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 102 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Washington, which has 1,048 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Leuprolide Acetate is the first listed.
NCT00223665 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00223665 about?
NCT00223665 is a clinical study titled "Effects of IAS in Men With Localized Biochemical Relapsed Prostate Cancer". This study was a prospective analysis in men with localized prostate cancer who had rising Prostate Specific Antigen (PSA) levels after definitive treatment with surgery or radiation. Patients received Intermittent Androgen Suppression (IAS) in 9 month cycles until they became metastatic, became cas...
What is the current status of trial NCT00223665?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 102 participants. The study started on 1997-01-08. Estimated completion is 2012-09-06.
What interventions are being tested in trial NCT00223665?
The interventions under investigation include: Leuprolide Acetate (DRUG), Flutamide (DRUG).
Who is sponsoring clinical trial NCT00223665?
This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.